BerandaBCRX • NASDAQ
add
BioCryst Pharmaceuticals Inc
$7,63
Setelah Jam Perdagangan Normal:(0,39%)-0,030
$7,60
Tutup: 16 Jul, 18.56.47 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$7,18
Rentang hari
$7,26 - $7,64
Rentang tahun
$4,03 - $7,95
Kapitalisasi pasar
1,57Â M USD
Volume Rata-Rata
3,38Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 92,76Â jt | 34,87% |
Biaya operasional | 59,36Â jt | 24,02% |
Laba bersih | -35,38Â jt | 33,66% |
Margin laba bersih | -38,14 | 50,81% |
Penghasilan per saham | -0,17 | 39,29% |
EBITDA | -14,18Â jt | 49,37% |
Tarif pajak efektif | -1,04% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 336,55Â jt | -15,47% |
Total aset | 467,89Â jt | -8,21% |
Total liabilitas | 944,06Â jt | 12,65% |
Total ekuitas | -476,17 jt | — |
Saham yang beredar | 206,38 jt | — |
Harga terhadap reservasi | -3,11 | — |
Tingkat pengembalian aset | -7,36% | — |
Pengembalian modal | -9,41% | — |
Arus Kas
Perubahan bersih tunai
| (USD) | Mar 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -35,38Â jt | 33,66% |
Kas dari operasi | -53,68Â jt | -12,99% |
Tunai dari investasi | 28,76Â jt | 126,85% |
Tunai dari pembiayaan | -1,05Â jt | -120,64% |
Perubahan bersih tunai | -26,32Â jt | 82,41% |
Arus kas bebas | -46,83Â jt | -12,46% |
Tentang
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Didirikan
1986
Kantor pusat
Situs
Karyawan
536
